About this Research Topic
The field of lung transplantation has become a crucial treatment option for patients suffering from irreversible end-stage chronic respiratory failure. However, the procedure is not without its complications, such as acute cellular/humoral rejection (AR) and chronic rejection, which occur at a high frequency. These episodes of rejection often go unnoticed due to their lack of clinical symptoms or their close association with other graft-related events. Currently, the gold standard for diagnosing rejection relies on histopathological criteria, which involves invasive and risky lung sampling. This method is not only costly but also lacks reproducibility, highlighting the need for a better approach.
The primary aim of this research topic is to explore the potential of non-invasive biomarkers in the field of lung transplantation. The focus will be on the development and application of innovative, non-invasive, cost-effective, and reproducible tools for screening and/or diagnosing rejection. While research on non-invasive biomarkers is already being conducted in areas like oncology and prenatal diagnosis, it is still in its infancy in organ transplantation, particularly in the context of lung transplants.
The scope of this research topic is confined to the study of non-invasive biomarkers and their application in lung transplantation. We welcome articles addressing, but not limited to, the following themes:
- Studies on non-invasive biomarkers such as cfDNA, dd-cfDNA, circulating nucleic acids, biochemical biomarkers, DSA, etc.
- Research involving biomarkers in blood as well as in other biological or non-biological fluids (graft preservation fluid, etc.)
- Investigations into the potential of these biomarkers for early detection and diagnosis of rejection episodes.
- Exploration of the cost-effectiveness and reproducibility of non-invasive biomarker-based screening methods.
The primary aim of this research topic is to explore the potential of non-invasive biomarkers in the field of lung transplantation. The focus will be on the development and application of innovative, non-invasive, cost-effective, and reproducible tools for screening and/or diagnosing rejection. While research on non-invasive biomarkers is already being conducted in areas like oncology and prenatal diagnosis, it is still in its infancy in organ transplantation, particularly in the context of lung transplants.
The scope of this research topic is confined to the study of non-invasive biomarkers and their application in lung transplantation. We welcome articles addressing, but not limited to, the following themes:
- Studies on non-invasive biomarkers such as cfDNA, dd-cfDNA, circulating nucleic acids, biochemical biomarkers, DSA, etc.
- Research involving biomarkers in blood as well as in other biological or non-biological fluids (graft preservation fluid, etc.)
- Investigations into the potential of these biomarkers for early detection and diagnosis of rejection episodes.
- Exploration of the cost-effectiveness and reproducibility of non-invasive biomarker-based screening methods.
Keywords: Biomarkers, Lung Transplantation, Rejection, Acute Rejection, Chronic Rejection, Humoral Rejection, Cellular Rejection
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
